Advertisement

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Published:April 17, 2017DOI:https://doi.org/10.1016/j.jhep.2017.03.022

      Summary

      Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Beuers U.
        • Gershwin M.E.
        • Gish R.G.
        • Invernizzi P.
        • Jones D.E.
        • Lindor K.
        • et al.
        Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.
        J Hepatol. 2015; 63: 1285-1287
        • Selmi C.
        • Bowlus C.L.
        • Gershwin M.E.
        • Coppel R.L.
        Primary biliary cirrhosis.
        Lancet. 2011; 377: 1600-1609
        • Hirschfield G.M.
        • Gershwin M.E.
        The immunobiology and pathophysiology of primary biliary cirrhosis.
        Annu Rev Pathol. 2013; 8: 303-330
        • Beuers U.
        • Trauner M.
        • Jansen P.
        • Poupon R.
        New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
        J Hepatol. 2015; 62: S25-S37
        • Webb G.J.
        • Hirschfield G.M.
        Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances.
        Nat Rev Gastroenterol Hepatol. 2017; 14: 76-78
        • Carbone M.
        • Mells G.F.
        • Pells G.
        • Dawwas M.F.
        • Newton J.L.
        • Heneghan M.A.
        • et al.
        Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid.
        Gastroenterology. 2013; 144: 560-569
        • Lammers W.J.
        • van Buuren H.R.
        • Hirschfield G.M.
        • Janssen H.L.
        • Invernizzi P.
        • Mason A.L.
        • et al.
        Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
        Gastroenterology. 2014; 147: 1338-1349
        • Trivedi P.J.
        • Lammers W.J.
        • van Buuren H.R.
        • Pares A.
        • Floreani A.
        • Janssen H.L.
        • et al.
        Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.
        Gut. 2016; 65: 321-329
        • Dahlan Y.
        • Smith L.
        • Simmonds D.
        • Jewell L.D.
        • Wanless I.
        • Heathcote E.J.
        • et al.
        Pediatric-onset primary biliary cirrhosis.
        Gastroenterology. 2003; 125: 1476-1479
        • Invernizzi P.
        • Alessio M.G.
        • Smyk D.S.
        • Lleo A.
        • Sonzogni A.
        • Fabris L.
        • et al.
        Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature.
        BMC Gastroenterol. 2012; 12: 92
        • Juran B.D.
        • Lazaridis K.N.
        Environmental factors in primary biliary cirrhosis.
        Semin Liver Dis. 2014; 34: 265-272
        • Webb G.J.
        • Hirschfield G.M.
        Using GWAS to identify genetic predisposition in hepatic autoimmunity.
        J Autoimmun. 2016; 66: 25-39
        • Bianchi I.
        • Carbone M.
        • Lleo A.
        • Invernizzi P.
        Genetics and epigenetics of primary biliary cirrhosis.
        Semin Liver Dis. 2014; 34: 255-264
        • Jepsen P.
        • Gronbaek L.
        • Vilstrup H.
        Worldwide incidence of autoimmune liver disease.
        Dig Dis. 2015; 33: 2-12
        • Boonstra K.
        • Kunst A.E.
        • Stadhouders P.H.
        • Tuynman H.A.
        • Poen A.C.
        • van Nieuwkerk K.M.
        • et al.
        Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study.
        Liver Int. 2014; 34: e31-e38
        • Griffiths L.
        • Dyson J.K.
        • Jones D.E.
        The new epidemiology of primary biliary cirrhosis.
        Semin Liver Dis. 2014; 34: 318-328
        • Dahlqvist G.
        • Gaouar F.
        • Carrat F.
        • Meurisse S.
        • Chazouilleres O.
        • Poupon R.
        • et al.
        Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis.
        Hepatology. 2017; 65: 152-163
        • Lleo A.
        • Jepsen P.
        • Morenghi E.
        • Carbone M.
        • Moroni L.
        • Battezzati P.M.
        • et al.
        Evolving trends in female to male incidence and male mortality of primary biliary cholangitis.
        Sci Rep. 2016; 625906
        • Bianchi I.
        • Lleo A.
        • Gershwin M.E.
        • Invernizzi P.
        The X chromosome and immune associated genes.
        J Autoimmun. 2012; 38: J187-J192
        • Trivedi P.J.
        • Corpechot C.
        • Pares A.
        • Hirschfield G.M.
        Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.
        Hepatology. 2016; 63: 644-659
        • Trauner M.
        • Fuchs C.D.
        • Halilbasic E.
        • Paumgartner G.
        New therapeutic concepts in bile acid transport and signalling for management of cholestasis.
        Hepatology. 2017; 65: 1393-1404
        • Jansen P.L.
        • Ghallab A.
        • Vartak N.
        • Reif R.
        • Schaap F.G.
        • Hampe J.
        • et al.
        The ascending pathophysiology of cholestatic liver disease.
        Hepatology. 2017; 65: 722-738
        • Hirschfield G.M.
        • Liu X.
        • Xu C.
        • Lu Y.
        • Xie G.
        • Lu Y.
        • et al.
        Primary biliary cirrhosis associated with HLA, IL12A and IL12RB2 variants.
        N Engl J Med. 2009; 360: 2544-2555
        • Cordell H.J.
        • Han Y.
        • Mells G.F.
        • Li Y.
        • Hirschfield G.M.
        • Greene C.S.
        • et al.
        International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.
        Nat Commun. 2015; 6: 8019
        • Chang J.C.
        • Go S.
        • de Waart D.R.
        • Munoz-Garrido P.
        • Beuers U.
        • Paulusma C.C.
        • et al.
        Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes.
        Hepatology. 2016; 64: 522-534
        • Hisamoto S.
        • Shimoda S.
        • Harada K.
        • Iwasaka S.
        • Onohara S.
        • Chong Y.
        • et al.
        Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis.
        J Autoimmun. 2016; 75: 150-160
        • Beuers U.
        • Hohenester S.
        • de Buy Wenniger L.J.
        • Kremer A.E.
        • Jansen P.L.
        • Elferink R.P.
        The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies.
        Hepatology. 2010; 52: 1489-1496
        • Poupon R.
        Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation.
        Hepatology. 2015; 61: 2080-2090
        • Mells G.
        • Pells G.
        • Newton J.L.
        • Heneghan M.
        • Neuberger J.M.
        • Day D.
        • et al.
        The impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC National Study.
        Hepatology. 2013; 58: 273-283
        • Dyson J.K.
        • Wilkinson N.
        • Jopson L.
        • Mells G.
        • Bathgate A.
        • Heneghan M.A.
        • et al.
        The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.
        Aliment Pharmacol Ther. 2016; 44: 1039-1050
        • Prince M.I.
        • Chetwynd A.
        • Newman W.
        • Metcalf J.V.
        • James O.F.
        Survival and symptom progression in a geographically based cohort of paients with primary biliary cirrhosis: follow-up for up to 28 years.
        Gastroenterology. 2002; 123: 1044-1051
        • Mahl T.C.
        • Shockcor W.
        • Boyer J.L.
        Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years.
        J Hepatol. 1994; 20: 707-713
        • Christensen E.
        • Crowe J.
        • Doniach D.
        • Popper H.
        • Ranek L.
        • Rodes J.
        • et al.
        Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients.
        Gastroenterology. 1980; 78: 236-246
        • Locke 3rd, G.R.
        • Therneau T.M.
        • Ludwig J.
        • Dickson E.R.
        • Lindor K.D.
        Time course of histological progression in primary biliary cirrhosis.
        Hepatology. 1996; 23: 52-56
        • Corpechot C.
        • Carrat F.
        • Bonnand A.M.
        • Poupon R.E.
        • Poupon R.
        The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
        Hepatology. 2000; 32: 1196-1199
        • Shaneyfelt T.M.
        • Mayo-Smith M.F.
        • Rothwangl J.
        Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature.
        JAMA. 1999; 281: 1900-1905
        • European Association for the Study of the L
        EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
        J Hepatol. 2009; 51: 237-267
        • Chalasani N.P.
        • Hayashi P.H.
        • Bonkovsky H.L.
        • Navarro V.J.
        • Lee W.M.
        • Fontana R.J.
        • et al.
        ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.
        Am J Gastroenterol. 2014; 109: 950-966
        • Oertelt S.
        • Rieger R.
        • Selmi C.
        • Invernizzi P.
        • Ansari A.A.
        • Coppel R.L.
        • et al.
        A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis.
        Hepatology. 2007; 45: 659-665
        • Liu H.
        • Norman G.L.
        • Shums Z.
        • Worman H.J.
        • Krawitt E.L.
        • Bizzaro N.
        • et al.
        PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis.
        J Autoimmun. 2010; 35: 436-442
        • Leung P.S.
        • Rossaro L.
        • Davis P.A.
        • Park O.
        • Tanaka A.
        • Kikuchi K.
        • et al.
        Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis.
        Hepatology. 2007; 46: 1436-1442
        • Mattalia A.
        • Quaranta S.
        • Leung P.S.
        • Bauducci M.
        • Van de Water J.
        • Calvo P.L.
        • et al.
        Characterization of antimitochondrial antibodies in health adults.
        Hepatology. 1998; 27: 656-661
        • Ohba K.
        • Omagari K.
        • Kinoshita H.
        • Soda H.
        • Masuda J.
        • Hazama H.
        • et al.
        Primary biliary cirrhosis among atomic bomb survivors in Nagasaki, Japan.
        J Clin Epidemiol. 2001; 54: 845-850
        • Ong J.
        • Erdei E.
        • Rubin R.L.
        • Miller C.
        • Ducheneaux C.
        • O'Leary M.
        • et al.
        Mercury, autoimmunity, and environmental factors on cheyenne river sioux tribal lands.
        Autoimmune Dis. 2014; 2014325461
        • Lleo A.
        • Liao J.
        • Invernizzi P.
        • Zhao M.
        • Bernuzzi F.
        • Ma L.
        • et al.
        Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis.
        Hepatology. 2012; 55: 153-160
        • Christensen E.
        • Neuberger J.
        • Crowe J.
        • Portmann B.
        • Williams R.
        • Altman D.G.
        • et al.
        Azathioprine and prognosis in primary biliary cirrhosis.
        Gastroenterology. 1986; 90: 508-509
        • Poupon R.
        • Chazouilleres O.
        • Balkau B.
        • Poupon R.E.
        Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis, UDCA-PBC Group.
        J Hepatol. 1999; 30: 408-412
        • Corpechot C.
        • Poujol-Robert A.
        • Wendum D.
        • Galotte M.
        • Chretien Y.
        • Poupon R.E.
        • et al.
        Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
        Liver Int. 2004; 24: 187-193
        • Longo M.
        • Crosignani A.
        • Battezzati P.M.
        • Squarcia Giussani C.
        • Invernizzi P.
        • Zuin M.
        • et al.
        Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.
        Gut. 2002; 51: 265-269
        • Allocca M.
        • Crosignani A.
        • Gritti A.
        • Ghilardi G.
        • Gobatti D.
        • Caruso D.
        • et al.
        Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.
        Gut. 2006; 55: 1795-1800
        • Vergani D.
        • Alvarez F.
        • Bianchi F.B.
        • Cancado E.L.
        • Mackay I.R.
        • Manns M.P.
        • et al.
        Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.
        J Hepatol. 2004; 41: 677-683
        • Invernizzi P.
        • Lleo A.
        • Podda M.
        Interpreting serological tests in diagnosing autoimmune liver diseases.
        Semin Liver Dis. 2007; 27: 161-172
        • Metcalf J.V.
        • Mitchinson H.C.
        • Palmer J.M.
        • Jones D.E.J.
        • Bassendine M.F.
        • James O.F.W.
        Natural history of early primary biliary cirrhosis.
        Lancet. 1996; 348: 1399-1402
        • Hirschfield G.M.
        • Heathcote E.J.
        Antimitochondrial antibody-negative primary biliary cirrhosis.
        Clin Liver Dis. 2008; 12: 323-331
        • Ludwig J.
        • Dickson E.R.
        • McDonald G.S.
        Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).
        Virchows Arch. 1978; 379: 103-112
        • Scheuer P.
        Primary biliary cirrhosis.
        Proc R Soc Med. 1967; 60: 1257-1260
        • Scheuer P.J.
        Ludwig Symposium on biliary disorders–part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis.
        Mayo Clin Proc. 1998; 73: 179-183
        • Nakanuma Y.
        • Zen Y.
        • Harada K.
        • Sasaki M.
        • Nonomura A.
        • Uehara T.
        • et al.
        Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement.
        Pathol Int. 2010; 60: 167-174
        • Harada K.
        • Hsu M.
        • Ikeda H.
        • Zeniya M.
        • Nakanuma Y.
        Application and validation of a new histologic staging and grading system for primary biliary cirrhosis.
        J Clin Gastroenterol. 2013; 47: 174-181
        • Kakuda Y.
        • Harada K.
        • Sawada-Kitamura S.
        • Ikeda H.
        • Sato Y.
        • Sasaki M.
        • et al.
        Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems.
        Hum Pathol. 2013; 44: 1107-1117
        • ter Borg P.C.
        • Schalm S.W.
        • Hansen B.E.
        • van Buuren H.R.
        Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
        Am J Gastroenterol. 2006; 101: 2044-2050
        • Pares A.
        • Caballeria L.
        • Rodes J.
        Excellent long-term survival in patients with primary biliary cirrhosisand biochemical response to ursodeoxycholic acid.
        Gastroenterology. 2006; 130: 715-720
        • Corpechot C.
        • Abenavoli L.
        • Rabahi N.
        • Chretien Y.
        • Andreani T.
        • Johanet C.
        • et al.
        Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
        Hepatology. 2008; 48: 871-877
        • Kubota J.
        • Ikeda F.
        • Terada R.
        • Kobashi H.
        • Fujioka S.
        • Okamoto R.
        • et al.
        Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population.
        J Gastroenterol. 2009; 44: 1000-1006
        • Cheung A.
        • Lammers W.J.
        • Hirschfield G.M.
        • Invernizzi P.
        • Mason A.
        • Ponsioen C.Y.
        • et al.
        Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis.
        J Hepatol. 2015; 62: S798-S799
        • Quarneti C.
        • Muratori P.
        • Lalanne C.
        • Fabbri A.
        • Menichella R.
        • Granito A.
        • et al.
        Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis.
        Liver Int. 2015; 35: 636-641
        • Jones D.E.
        • Al-Rifai A.
        • Frith J.
        • Patanwala I.
        • Newton J.L.
        The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9 year follow-up.
        J Hepatol. 2010; 53: 911-917
        • Vleggaar F.P.
        • van Buuren H.R.
        • Zondervan P.E.
        • ten Kate F.J.
        • Hop W.C.
        • Dutch Multicentre PBC study group
        Jaundice in non-cirrhotic primary bilairy cirrhosis: the premature ductopenic variant.
        Gut. 2001; 49: 276-281
        • Jones D.E.
        • Bhala N.
        • Burt J.
        • Goldblatt J.
        • Prince M.
        • Newton J.L.
        Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.
        Gut. 2006; 55: 536-541
        • Prince M.I.
        • Chetwynd A.
        • Craig W.L.
        • Metcalf J.V.
        • James O.F.
        Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.
        Gut. 2004; 53: 865-870
        • Newton J.
        • Jones D.E.
        Variability of perceived fatigue in primary biliary cirrhosis: implications for symptom assessment.
        Liver Int. 2010; 30: 333-334
        • Shapiro J.M.
        • Smith H.
        • Schaffner F.
        Serum bilirubin: a prognostic factor in primary biliary cirrhosis.
        Gut. 1979; 20: 137-140
        • Kilmurry M.R.
        • Heathcote E.J.
        • Cauch-Dudek K.
        • O'Rourke K.
        • Bailey R.J.
        • Blendis L.M.
        • et al.
        Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?.
        Hepatology. 1996; 23: 1148-1153
        • Mayo M.J.
        • Parkes J.
        • Adams-Huet B.
        • Combes B.
        • Mills A.S.
        • Markin R.S.
        • et al.
        Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.
        Hepatology. 2008; 48: 1549-1557
        • Muratori P.
        • Muratori L.
        • Ferrari R.
        • Cassani F.
        • Bianchi G.
        • Lenzi M.
        • et al.
        Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.
        Am J Gastroenterol. 2003; 98: 431-437
        • Rigopoulou E.I.
        • Davies E.T.
        • Pares A.
        • Zachou K.
        • Liaskos C.
        • Bogdanos D.P.
        • et al.
        Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.
        Gut. 2005; 54: 528-532
        • Wesierska-Gadek J.
        • Penner E.
        • Battezzati P.M.
        • Selmi C.
        • Zuin M.
        • Hitchman E.
        • et al.
        Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.
        Hepatology. 2006; 43: 1135-1144
        • Nakamura M.
        • Kondo H.
        • Tanaka A.
        • Komori A.
        • Ito M.
        • Yamamoto K.
        • et al.
        Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis.
        Hepatol Res. 2015; 45: 846-855
        • Rigamonti C.
        • Shand L.M.
        • Feudjo M.
        • Bunn C.C.
        • Black C.M.
        • Denton C.P.
        • et al.
        Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.
        Gut. 2006; 55: 388-394
        • Nakamura M.
        • Kondo H.
        • Mori T.
        • Komori A.
        • Matsuyama M.
        • Ito M.
        • et al.
        Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.
        Hepatology. 2007; 45: 118-127
        • Nyberg A.
        • Engstrom-Laurent A.
        • Loof L.
        Serum hyaluronate in primary biliary cirrhosis–a biochemical marker for progressive liver damage.
        Hepatology. 1988; 8: 142-146
        • Poupon R.E.
        • Balkau B.
        • Guechot J.
        • Heintzmann F.
        Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue.
        Hepatology. 1994; 19: 635-640
        • Trivedi P.J.
        • Bruns T.
        • Cheung A.
        • Li K.K.
        • Kittler C.
        • Kumagi T.
        • et al.
        Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
        J Hepatol. 2014; 60: 1249-1258
        • Umemura T.
        • Joshita S.
        • Sekiguchi T.
        • Usami Y.
        • Shibata S.
        • Kimura T.
        • et al.
        Serum wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis.
        Am J Gastroenterol. 2015; 110: 857-864
        • Sekiguchi T.
        • Umemura T.
        • Fujimori N.
        • Shibata S.
        • Ichikawa Y.
        • Kimura T.
        • et al.
        Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis.
        PLoS One. 2015; 10e0131658
        • Corpechot C.
        • Carrat F.
        • Poujol-Robert A.
        • Gaouar F.
        • Wendum D.
        • Chazouilleres O.
        • et al.
        Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis.
        Hepatology. 2012; 56: 198-208
        • Floreani A.
        • Cazzagon N.
        • Martines D.
        • Cavalletto L.
        • Baldo V.
        • Chemello L.
        Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis.
        Dig Liver Dis. 2011; 43: 887-892
        • Gomez-Dominguez E.
        • Mendoza J.
        • Garcia-Buey L.
        • Trapero M.
        • Gisbert J.P.
        • Jones E.A.
        • et al.
        Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis.
        Aliment Pharmacol Ther. 2008; 27: 441-447
        • European Association for Study of Liver
        • Asociacion Latinoamericana para el Estudio del Higado
        EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
        J Hepatol. 2015; 63: 237-264
        • Corpechot C.
        • Gaouar F.
        • Lemoinne S.
        • Ben Belkacem K.
        • Kemgang Fankem A.
        • Chretien Y.
        • et al.
        Relationships between biochemical response to UDCA and progression of liver stiffness as determined by Fibroscan in patients with PBC.
        Hepatology. 2016; 64: 194A-195A
        • Corpechot C.
        • Gaouar F.
        • Lemoinne S.
        • Kemgang Fankem A.
        • Poupon R.
        • Chretien Y.
        • et al.
        Fibroscan improves the ability of the new prognostic scoring systems to predict outcomes of PBC.
        J Hepatol. 2016; 64: S177-S178
        • Boursier J.
        • Zarski J.P.
        • de Ledinghen V.
        • Rousselet M.C.
        • Sturm N.
        • Lebail B.
        • et al.
        Determination of reliability criteria for liver stiffness evaluation by transient elastography.
        Hepatology. 2013; 57: 1182-1191
        • Roll J.
        • Boyer J.L.
        • Barry D.
        • Klatskin G.
        The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis.
        N Engl J Med. 1983; 308: 1-7
        • Poupon R.E.
        • Bonnand A.M.
        • Chretien Y.
        • Poupon R.
        Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
        Hepatology. 1999; 29: 1668-1671
        • Carbone M.
        • Sharpe S.J.
        • Heneghan M.A.
        • Neuberger J.
        • Hirschfield G.M.
        • Burroughs A.
        • et al.
        Histological stage is relevant for risk-stratification in primary biliary cirrhosis.
        J Hepatol. 2015; 62: S805
        • Rabahi N.
        • Chretien Y.
        • Gaouar F.
        • Wendum D.
        • Serfaty L.
        • Chazouilleres O.
        • et al.
        Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
        Gastroenterol Clin Biol. 2010; 34: 283-287
        • Corpechot C.
        • Carrat F.
        • Poupon R.
        • Poupon R.E.
        Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.
        Gastroenterology. 2002; 122: 652-658
        • Kumagi T.
        • Guindi M.
        • Fischer S.E.
        • Arenovich T.
        • Abdalian R.
        • Coltescu C.
        • et al.
        Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.
        Am J Gastroenterol. 2010; 105: 2186-2194
        • Huet P.M.
        • Vincent C.
        • Deslaurier J.
        • Cote J.
        • Matsutami S.
        • Boileau R.
        • et al.
        Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment.
        Gastroenterology. 2008; 135: 1552-1560
        • Silveira M.G.
        • Brunt E.M.
        • Heathcote J.
        • Gores G.J.
        • Lindor K.D.
        • Mayo M.J.
        American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis.
        Hepatology. 2010; 52: 349-359
        • Angulo P.
        • Lindor K.D.
        • Therneau T.M.
        • Jorgensen R.A.
        • Malinchoc M.
        • Kamath P.S.
        • et al.
        Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.
        Liver. 1999; 19: 115-121
        • Kuiper E.M.
        • Hansen B.E.
        • de Vries R.A.
        • den Ouden-Muller J.W.
        • van Ditzhuijsen T.J.
        • Haagsma E.B.
        • et al.
        Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
        Gastroenterology. 2009; 136: 1281-1287
        • Azemoto N.
        • Abe M.
        • Murata Y.
        • Hiasa Y.
        • Hamada M.
        • Matsuura B.
        • et al.
        Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis.
        J Gastroenterol. 2009; 44: 630-634
        • Corpechot C.
        • Chazouilleres O.
        • Poupon R.
        Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
        J Hepatol. 2011; 55: 1361-1367
        • Zhang L.N.
        • Shi T.Y.
        • Shi X.H.
        • Wang L.
        • Yang Y.J.
        • Liu B.
        • et al.
        Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study.
        Hepatology. 2013; 58: 264-272
        • Lammers W.J.
        • Hirschfield G.M.
        • Corpechot C.
        • Nevens F.
        • Lindor K.D.
        • Janssen H.L.
        • et al.
        Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy.
        Gastroenterology. 2015; 149: 1804-1812
        • Carbone M.
        • Sharp S.J.
        • Flack S.
        • Paximadas D.
        • Spiess K.
        • Adgey C.
        • et al.
        The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis.
        Hepatology. 2016; 63: 930-950
        • Hansen B.
        • Lammers W.J.
        • Jones D.
        • van Buuren H.
        • Mells G.F.
        • Carbone M.
        Convergence of Two Predictive Models of Risk Reduction in Patients with Primary Biliary Cirrhosis.
        Hepatology. 2016; 62: 507A
        • Lindor K.
        Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
        N Engl J Med. 2007; 357: 1524-1529
        • Lindor K.D.
        • Gershwin M.E.
        • Poupon R.
        • Kaplan M.
        • Bergasa N.
        • Heathcote E.
        Primary biliary cirrhosis.
        Hepatology. 2009; 50: 291-308
      1. Hirschfield G.M. Heathcote E.J. Primary biliary cirrhosis: evidence-based gastroenterology and hepatology. 3rd ed. Wiley-Blackwell, Oxford, UK2010https://doi.org/10.1002/9781444314403 (Chapter 3)
        • Poupon R.E.
        • Poupon R.
        • Balkau B.
        Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.
        N Engl J Med. 1994; 330: 1342-1347
        • Lindor K.D.
        • Dickson E.R.
        • Baldus W.P.
        • Jorgensen R.A.
        • Ludwig J.
        • Murtaugh P.A.
        • et al.
        Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.
        Gastroenterology. 1994; 106: 1284-1290
        • Heathcote E.J.
        • Cauch-Dudek K.
        • Walker V.
        • Bailey R.J.
        • Blendis L.M.
        • Ghent C.N.
        • et al.
        The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
        Hepatology. 1994; 19: 1149-1156
        • Turner I.B.
        • Myszor M.
        • Mitchison H.C.
        • Bennett M.K.
        • Burt A.D.
        • James O.F.
        A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis.
        J Gastroenterol Hepatol. 1994; 9: 162-168
        • Poupon R.E.
        • Lindor K.D.
        • Cauch-Dudek K.
        • Dickson E.R.
        • Poupon R.
        • Heathcote E.J.
        Combined analysis of randomized trials of ursodeoxycholic acid in primary biliary cirrhosis.
        Gastroenterology. 1997; 113: 884-890
        • Combes B.
        • Carithers Jr., R.L.
        • Maddrey W.C.
        • Lin D.
        • McDonald M.F.
        • Wheeler D.E.
        • et al.
        A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.
        Hepatology. 1995; 22: 759-766
        • Van Hoogstraten H.J.
        • De Smet M.B.
        • Renooij W.
        • Breed J.G.
        • Engels L.G.
        • Den Ouden-Muller J.W.
        • et al.
        A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
        Aliment Pharmacol Ther. 1998; 12: 965-971
        • Goulis J.
        • Leandro G.
        • Burroughs A.K.
        Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.
        Lancet. 1999; 354: 1053-1060
        • Shi J.
        • Wu C.
        • Lin Y.
        • Chen Y.X.
        • Zhu L.
        • Xie W.F.
        Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
        Am J Gastroenterol. 2006; 101: 1529-1538
        • Rudic J.S.
        • Poropat G.
        • Krstic M.N.
        • Bjelakovic G.
        • Gluud C.
        Ursodeoxycholic acid for primary biliary cirrhosis.
        Cochrane Database Syst Rev. 2012; 12: CD000551
        • Beuers U.
        Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
        Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 318-328
        • Gohlke H.
        • Schmitz B.
        • Sommerfeld A.
        • Reinehr R.
        • Haussinger D.
        alpha5 beta1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes.
        Hepatology. 2013; 57: 1117-1129
        • Dilger K.
        • Hohenester S.
        • Winkler-Budenhofer U.
        • Bastiaansen B.A.
        • Schaap F.G.
        • Rust C.
        • et al.
        Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
        J Hepatol. 2012; 57: 133-140
        • Kondrackiene J.
        • Beuers U.
        • Kupcinskas L.
        Efficacy and safety of ursodeoxycholic acid vs. cholestyramine in intrahepatic cholestasis of pregnancy.
        Gastroenterology. 2005; 129: 894-901
        • Bacq Y.
        • Sentilhes L.
        • Reyes H.B.
        • Glantz A.
        • Kondrackiene J.
        • Binder T.
        • et al.
        Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
        Gastroenterology. 2012; 143: 1492-1501
        • Gong Y.
        • Huang Z.
        • Christensen E.
        • Gluud C.
        Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses.
        Am J Gastroenterol. 2007; 102: 1799-1807
        • Schaap F.G.
        • Trauner M.
        • Jansen P.L.
        Bile acid receptors as targets for drug development.
        Nat Rev Gastroenterol Hepatol. 2014; 11: 55-67
        • Gomez-Ospina N.
        • Potter C.J.
        • Xiao R.
        • Manickam K.
        • Kim M.S.
        • Kim K.H.
        • et al.
        Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.
        Nat Commun. 2016; 710713
        • Hirschfield G.M.
        • Mason A.
        • Luketic V.
        • Lindor K.
        • Gordon S.C.
        • Mayo M.
        • et al.
        Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
        Gastroenterology. 2015; 148: 751-761
        • Nevens F.
        • Andreone P.
        • Mazzella G.
        • Strasser S.I.
        • Bowlus C.
        • Invernizzi P.
        • et al.
        A placebo-controlled trial of obeticholic acid in primary biliary cholangitis.
        N Engl J Med. 2016; 375: 631-643
        • Hempfling W.
        • Grunhage F.
        • Dilger K.
        • Reichel C.
        • Beuers U.
        • Sauerbruch T.
        Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis.
        Hepatology. 2003; 38: 196-202
        • Arenas F.
        • Hervias I.
        • Uriz M.
        • Joplin R.
        • Prieto J.
        • Medina J.F.
        Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
        J Clin Invest. 2008; 118: 695-709
        • Leuschner M.
        • Maier K.P.
        • Schlichting J.
        • Strahl S.
        • Herrmann G.
        • Dahm H.H.
        • et al.
        Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
        Gastroenterology. 1999; 117: 918-925
        • Rautiainen H.
        • Karkkainen P.
        • Karvonen A.L.
        • Nurmi H.
        • Pikkarainen P.
        • Nuutinen H.
        • et al.
        Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
        Hepatology. 2005; 41: 747-752
        • Angulo P.
        • Jorgensen R.A.
        • Keach J.C.
        • Dickson E.R.
        • Smith C.
        • Lindor K.D.
        Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
        Hepatology. 2000; 31: 318-323
        • Zhu G.Q.
        • Huang S.
        • Huang G.Q.
        • Wang L.R.
        • Lin Y.Q.
        • Wu Y.M.
        • et al.
        Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis.
        Oncotarget. 2015; 6: 24533-24549
        • Zhu G.Q.
        • Shi K.Q.
        • Huang S.
        • Huang G.Q.
        • Lin Y.Q.
        • Zhou Z.R.
        • et al.
        Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis.
        Medicine. 2015; 94e609
        • Ghonem N.S.
        • Assis D.N.
        • Boyer J.L.
        Fibrates and cholestasis.
        Hepatology. 2015; 62: 635-643
        • Yin Q.
        • Li J.
        • Xia Y.
        • Zhang R.
        • Wang J.
        • Lu W.
        • et al.
        Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.
        Drug Des Devel Ther. 2015; 9: 5407-5419
        • Tanaka A.
        • Hirohara J.
        • Nakanuma Y.
        • Tsubouchi H.
        • Takikawa H.
        Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
        J Gastroenterol. 2015; 50: 675-682
        • Kanda T.
        • Yokosuka O.
        • Imazeki F.
        • Saisho H.
        Bezafibrate treatment: a new medical approach for PBC patients?.
        J Gastroenterol. 2003; 38: 573-578
        • Hosonuma K.
        • Sato K.
        • Yamazaki Y.
        • Yanagisawa M.
        • Hashizume H.
        • Horiguchi N.
        • et al.
        A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
        Am J Gastroenterol. 2015; 110: 423-431
        • Lens S.
        • Leoz M.
        • Nazal L.
        • Bruguera M.
        • Pares A.
        Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
        Liver Int. 2014; 34: 197-203
        • Ohira H.
        • Sato Y.
        • Ueno T.
        • Sata M.
        Fenofibrate treatment in patients with primary biliary cirrhosis.
        Am J Gastroenterol. 2002; 97: 2147-2149
        • Levy C.
        • Peter J.A.
        • Nelson D.R.
        • Keach J.
        • Petz J.
        • Cabrera R.
        • et al.
        Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
        Aliment Pharmacol Ther. 2011; 33: 235-242
        • Grigorian A.Y.
        • Mardini H.E.
        • Corpechot C.
        • Poupon R.
        • Levy C.
        Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.
        Clin Res Hepatol Gastroenterol. 2015; 39: 296-306
        • Cheung A.C.
        • Lapointe-Shaw L.
        • Kowgier M.
        • Meza-Cardona J.
        • Hirschfield G.M.
        • Janssen H.L.
        • et al.
        Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
        Aliment Pharmacol Ther. 2016; 43: 283-293
        • Yano K.
        • Kato H.
        • Morita S.
        • Takahara O.
        • Ishibashi H.
        • Furukawa R.
        Is bezafibrate histologically effective for primary biliary cirrhosis?.
        Am J Gastroenterol. 2002; 97: 1075-1077
        • Kurihara T.
        • Maeda A.
        • Shigemoto M.
        • Yamashita K.
        • Hashimoto E.
        Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy.
        Am J Gastroenterol. 2002; 97: 212-214
        • Hegade V.S.
        • Khanna A.
        • Walker L.J.
        • Wong L.L.
        • Dyson J.K.
        • Jones D.E.
        Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but Not the UK-PBC risk score.
        Dig Dis Sci. 2016; 61: 3037-3044
        • Zhang Y.
        • Li S.
        • He L.
        • Wang F.
        • Chen K.
        • Li J.
        • et al.
        Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
        Drug Des Devel Ther. 2015; 9: 2757-2766
        • Trivedi P.J.
        • Kumagi T.
        • Al-Harthy N.
        • Coltescu C.
        • Ward S.
        • Cheung A.
        • et al.
        Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis.
        Clin Gastroenterol Hepatol. 2014; 12: 1179-1185
        • Geenes V.
        • Chambers J.
        • Khurana R.
        • Shemer E.W.
        • Sia W.
        • Mandair D.
        • et al.
        Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy.
        Eur J Obstet Gynecol Reprod Biol. 2015; 189: 59-63
        • Alallam A.
        • Barth D.
        • Heathcote E.J.
        Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports.
        Can J Gastroenterol. 2008; : 505-507
        • Boberg K.M.
        • Chapman R.W.
        • Hirschfield G.M.
        • Lohse A.W.
        • Manns M.P.
        • Schrumpf E.
        • et al.
        Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue.
        J Hepatol. 2011; 54: 374-385
        • Trivedi P.J.
        • Hirschfield G.M.
        Review article: overlap syndromes and autoimmune liver disease.
        Aliment Pharmacol Ther. 2012; 36: 517-533
        • Czaja A.J.
        Cholestatic phenotypes of autoimmune hepatitis.
        Clin Gastroenterol Hepatol. 2014; 12: 1430-1438
        • Lindgren S.
        • Glaumann H.
        • Almer S.
        • Bergquist A.
        • Bjornsson E.
        • Broome U.
        • et al.
        Transitions between variant forms of primary biliary cirrhosis during long-term follow-up.
        Eur J Intern Med. 2009; 20: 398-402
        • Poupon R.
        • Chazouilleres O.
        • Corpechot C.
        • Chretien Y.
        Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis.
        Hepatology. 2006; 44: 85-90
        • Efe C.
        • Ozaslan E.
        • Heurgue-Berlot A.
        • Kav T.
        • Masi C.
        • Purnak T.
        • et al.
        Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis.
        Eur J Gastroenterol Hepatol. 2014; 26: 532-537
        • Chazouilleres O.
        • Wendum D.
        • Serfaty L.
        • Montembault S.
        • Rosmorduc O.
        • Poupon R.
        Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
        Hepatology. 1998; 28: 296-301
        • European Association for the Study of the Liver
        EASL Clinical Practice Guidelines: autoimmune hepatitis.
        J Hepatol. 2015; 63: 971-1004
        • Manns M.P.
        • Czaja A.J.
        • Gorham J.D.
        • Krawitt E.L.
        • Mieli-Vergani G.
        • Vergani D.
        • et al.
        Diagnosis and management of autoimmune hepatitis.
        Hepatology. 2010; 51: 2193-2213
        • Alvarez F.
        • Berg P.A.
        • Bianchi F.B.
        • Bianchi L.
        • Burroughs A.K.
        • Cancado E.L.
        • et al.
        International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.
        J Hepatol. 1999; 31: 929-938
        • Hennes E.M.
        • Zeniya M.
        • Czaja A.J.
        • Pares A.
        • Dalekos G.N.
        • Krawitt E.L.
        • et al.
        Simplified criteria for the diagnosis of autoimmune hepatitis.
        Hepatology. 2008; 48: 169-176
        • Eyraud V.
        • Chazouilleres O.
        • Ballot E.
        • Corpechot C.
        • Poupon R.
        • Johanet C.
        Significance of antibodies to soluble liver antigen/liver pancreas: a large French study.
        Liver Int. 2009; 29: 857-864
        • Kanzler S.
        • Bozkurt S.
        • Herkel J.
        • Galle P.R.
        • Dienes H.P.
        • Lohse A.W.
        Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome).
        Dtsch Med Wochenschr. 2001; 126: 450-456
        • Muratori P.
        • Granito A.
        • Pappas G.
        • Pendino G.M.
        • Quarneti C.
        • Cicola R.
        • et al.
        The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome.
        Am J Gastroenterol. 2009; 104: 1420-1425
        • Czaja A.J.
        • Carpenter H.A.
        Autoimmune hepatitis with incidental histologic features of bile duct injury.
        Hepatology. 2001; 34: 659-665
        • O'Brien C.
        • Joshi S.
        • Feld J.J.
        • Guindi M.
        • Dienes H.P.
        • Heathcote E.J.
        Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis.
        Hepatology. 2008; 48: 550-556
        • Dinani A.M.
        • Fischer S.E.
        • Mosko J.
        • Guindi M.
        • Hirschfield G.M.
        Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis.
        Clin Gastroenterol Hepatol. 2012; 10: 682-684
        • Neuhauser M.
        • Bjornsson E.
        • Treeprasertsuk S.
        • Enders F.
        • Silveira M.
        • Talwalkar J.
        • et al.
        Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis.
        Am J Gastroenterol. 2010; 105: 345-353
        • Yang F.
        • Wang Q.
        • Wang Z.
        • Miao Q.
        • Xiao X.
        • Tang R.
        • et al.
        The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis.
        Clin Rev Allergy Immunol. 2016; 50: 114-123
        • Ozaslan E.
        • Efe C.
        • Heurgue-Berlot A.
        • Kav T.
        • Masi C.
        • Purnak T.
        • et al.
        Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
        Clin Gastroenterol Hepatol. 2014; 12: 863-869
        • Chazouilleres O.
        • Wendum D.
        • Serfaty L.
        • Rosmorduc O.
        • Poupon R.
        Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
        J Hepatol. 2006; 44: 400-406
        • Czaja A.J.
        Frequency and nature of the variant syndromes of autoimmune liver disease.
        Hepatology. 1998; 28: 360-365
        • Al-Chalabi T.
        • Portmann B.C.
        • Bernal W.
        • McFarlane I.G.
        • Heneghan M.A.
        Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival.
        Aliment Pharmacol Ther. 2008; 28: 209-220
        • Wang Q.
        • Selmi C.
        • Zhou X.
        • Qiu D.
        • Li Z.
        • Miao Q.
        • et al.
        Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.
        J Autoimmun. 2013; 41: 140-145
        • Lohse A.W.
        • zum Buschenfelde K.H.
        • Franz B.
        • Kanzler S.
        • Gerken G.
        • Dienes H.P.
        Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals.
        Hepatology. 1999; 29: 1078-1084
        • Jacoby A.
        • Rannard A.
        • Buck D.
        • Bhala N.
        • Newton J.L.
        • James O.F.W.
        • et al.
        Development, validation and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.
        Gut. 2005; 54: 1622-1629
        • Newton J.L.
        • Bhala N.
        • Burt J.
        • Jones D.E.J.
        Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure.
        J Hepatol. 2006; 44: 776-782
        • Beuers U.
        • Kremer A.E.
        • Bolier R.
        • Elferink R.P.
        Pruritus in cholestasis: facts and fiction.
        Hepatology. 2014; 60: 399-407
        • Sherlock S.
        • Scheuer P.J.
        The presentation and diagnosis of 100 patients with primary biliary cirrhosis.
        N Engl J Med. 1973; 289: 674-678
        • Summerfield J.A.
        • Elias E.
        • Hungerford G.D.
        • Nikapota V.L.
        • Dick R.
        • Sherlock S.
        The biliary system in primary biliary cirrhosis. A study by endoscopic retrograde cholangiopancreatography.
        Gastroenterology. 1976; 70: 240-243
        • Datta D.V.
        • Sherlock S.
        Cholestyramine for long term relief of the priritus complicating intrahepatic cholestasis.
        Gastroenterology. 1966; 50: 323-332
        • Rust C.
        • Sauter G.H.
        • Oswald M.
        • Buttner J.
        • Kullak-Ublick G.A.
        • Paumgartner G.
        • et al.
        Effect of cholestyramine on bile acid patterns and synthesis during administration of ursodeoxycholic acid in man.
        Eur J Clin Invest. 2000; 30: 135-139
        • Kuiper E.M.
        • van Erpecum K.J.
        • Beuers U.
        • Hansen B.E.
        • Thio H.B.
        • de Man R.A.
        • et al.
        The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.
        Hepatology. 2010; 52: 1334-1340
        • Kremer A.E.
        • van Dijk R.
        • Leckie P.
        • Schaap F.G.
        • Kuiper E.M.M.
        • Mettang T.
        • et al.
        Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions.
        Hepatology. 2012; 56: 1391-1400
        • Ghent C.N.
        • Carruthers S.G.
        Treatment of pruritus in primary biliary cirrhosis with rifampicin. Results of a double-blind, crossover, randomized trial.
        Gastroenterology. 1988; 94: 488-493
        • Bachs L.P.
        • Pares A.
        • Elena M.
        • Piera C.
        • Rodes J.
        Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis.
        Lancet. 1989; 1: 574-576
        • Podesta A.L.
        • Terg P.
        • Villamil R.
        • Flores F.
        • Mastai D.
        • Udaondo R.
        • et al.
        Treatment of pruritus in primary biliary cirrhosis with rifampicin. Results of a double-blind, cross-over, randomized trial.
        Gastroenterology. 1991; 94: 488-493
        • Bachs L.P.
        • Elena M.
        • Piera M.
        • Rodes J.
        Effects of long-term rifampicin administration in primary biliary cirrhosis.
        Gastroenterology. 1992; 102: 2077-2080
        • Tandon P.
        • Rowe B.H.
        • Vandermeer B.
        • Bain V.G.
        The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis-associated pruritus.
        Am J Gastroenterol. 2007; 102: 1528-1536
        • Khurana S.
        • Singh P.
        Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials.
        Liver Int. 2006; 26: 943-948
        • Prince M.I.
        • Burt A.D.
        • Jones D.E.J.
        Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.
        Gut. 2002; 50: 436-439
        • Sampaziotis F.
        • Griffiths W.J.
        Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus.
        Br J Clin Pharmacol. 2012; 73: 826-827
        • Bergasa N.V.
        • Talbot T.L.
        • Alling D.W.
        • Schmitt J.M.
        • Walker E.C.
        • Baker B.L.
        • et al.
        A controlled trial of naloxone infusions for the pruritus of chronic cholestasis.
        Gastroenterology. 1992; 102: 544-549
        • Wolfhagen F.H.J.
        • Sternieri E.
        • Hop W.C.J.
        • Vitale G.
        • Bertoletti M.
        • Van Buuren H.R.
        Oral naltrexone for cholestatic pruritus-a double-blind, placebo-controlled study.
        Gastroenterology. 1997; 113: 1264-1269
        • Terg R.
        • Coronel E.
        • Sorda J.
        • Munoz A.E.
        • Findor J.
        Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.
        J Hepatol. 2002; 37: 717-722
        • Jones E.A.
        • Neuberger J.M.
        • Bergasa N.V.
        Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions.
        Q J Med. 2002; 95: 547-552
        • McRae C.A.
        • Prince M.I.
        • Hudson M.
        • Day C.P.
        • James O.F.W.
        • Jones D.E.J.
        Pain as a complication of use of opiate antagonists for symptom control in cholestasis.
        Gastroenterology. 2003; 125: 591-596
        • Jones E.A.
        • Dekker R.L.
        Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis.
        Gastroenterology. 2000; 118: 431-432
        • Mayo M.J.
        • Handem I.
        • Saldana S.
        • Jacobe H.
        • Getachew Y.
        • Rush A.J.
        Sertraline as a first-line treatment for cholestatic pruritus.
        Hepatology. 2007; 45: 666-674
        • Bergasa N.V.
        • McGee M.
        • Ginsburg I.H.
        • Engler D.
        Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial.
        Hepatology. 2006; 44: 1317-1323
        • Beuers U.
        • Gerken G.
        • Pusl T.
        Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis.
        Hepatology. 2006; 44: 280-281
        • Hofmann A.F.
        • Huet P.M.
        Nasobiliary drainage for cholestatic pruritus.
        Hepatology. 2006; 43: 1170-1171
        • Hegade V.S.
        • Krawczyk M.
        • Kremer A.E.
        • Kuczka J.
        • Gaouar F.
        • Kuiper E.M.
        • et al.
        The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study.
        Aliment Pharmacol Ther. 2016; 43: 294-302
        • Pares A.
        • Herrera M.
        • Aviles J.
        • Sanz M.
        • Mas A.
        Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers.
        J Hepatol. 2010; 53: 307-312
        • Decock S.
        • Roelandts R.
        • Steenbergen W.V.
        • Laleman W.
        • Cassiman D.
        • Verslype C.
        • et al.
        Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study.
        J Hepatol. 2012; 57: 637-641
        • Leckie P.
        • Tritto G.
        • Mookerjee R.
        • Davies N.
        • Jones D.E.J.
        • Jalan R.
        “Out-patient” albumin dialysis for cholestatic patients with intractable itch.
        Aliment Pharmacol Therap. 2012; 35: 696-704
        • Gross C.R.
        • Malinchoc M.
        • Kim W.R.
        • Evans R.W.
        • Wiesner R.H.
        • Petz J.L.
        • et al.
        Quality of life before and after liver transplantation for cholestatic liver disease.
        Hepatology. 1999; 29: 356-364
        • Kremer A.E.
        • martens J.J.
        • Kulik W.
        • Rueff F.
        • Kuiper E.M.
        • van Buuren H.R.
        • et al.
        Lysophosphatidic acid is a potential mediator of cholestatic pruritus.
        Gastroenterology. 2010; 139: 1008-1018
        • Hegade V.S.
        • Kendrick S.F.
        • Dobbins R.L.
        • Miller S.R.
        • Thompson D.
        • Richards D.
        • et al.
        Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
        Lancet. 2017; 389: 1114-1123
        • Huet P.-M.
        • Deslauriers J.
        • Faucher C.
        • Charbonneau J.
        Fatigue, mental health and depression in patients with primary biliary cirrhosis (PBC).
        Hepatology. 1996; 24: 167A
        • Cauch-Dudek K.
        • Abbey S.
        • Stewart D.E.
        • Heathcote E.J.
        Fatigue in primary biliary cirrhosis.
        Gut. 1998; 43: 705-710
        • Huet P.M.
        • Deslauriers J.
        • Tran A.
        • Faucher C.
        • Charbonneau J.
        Impact of fatigue on the quality of life in patients with primary biliary cirrhosis.
        Am J Gastroenterol. 2000; 95: 760-767
        • Goldblatt J.
        • Taylor P.J.S.
        • Lipman T.
        • Prince M.
        • Baragiotta M.
        • Bassendine M.F.
        • et al.
        The true impact of fatigue in primary biliary cirrhosis: a population study.
        Gastroenterology. 2002; 122: 1235-1241
        • Newton J.L.
        • Hollingsworth K.G.
        • Taylor R.
        • El-Sharkawy A.M.
        • Khan Z.U.
        • Pearce R.
        • et al.
        Cognitive impairment in primary biliary cirrhosis: symtpom impact and potential aetiology.
        Hepatology. 2008; 48: 541-549
        • Hollingsworth K.G.
        • Newton J.L.
        • Taylor R.
        • McDonald C.
        • Palmer J.M.
        • Blamire A.M.
        • et al.
        A pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis.
        Clin Gastroenterol Hepatol. 2008; 6: 1041-1048
        • Carbone M.
        • Bufton S.
        • Monaco A.
        • Griffiths L.
        • Jones D.E.
        • Neuberger J.M.
        The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study.
        J Hepatol. 2013; 59: 490-494
        • Jones D.E.
        • Sutcliffe K.
        • Pairman J.
        • Wilton K.
        • Newton J.L.
        An integrated care pathway improves quality of life in Primary Biliary Cirrhosis.
        QJM. 2008; 101: 535-543
        • Watt F.E.
        • James O.F.W.
        • Jones D.E.J.
        Patterns of autoimmunity in PBC patients and their families.
        QJM. 2004; 97: 397-406
        • Hollingsworth K.G.
        • Newton J.L.
        • Robinson L.
        • Taylor R.
        • Blamire A.M.
        • Jones D.E.J.
        Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis.
        J Hepatol. 2010; 53: 155-161
        • Mang F.W.
        • Michieletti P.
        • O'Rourke K.
        • Cauch-Dudek K.
        • Diamant N.
        • Bookman A.
        • et al.
        Primary biliary cirrhosis, sicca complex, and dysphagia.
        Dysphagia. 1997; 12: 167-170
        • Tsifetaki N.
        • Kitsos G.
        • Paschides C.A.
        • Alamanos Y.
        • Eftaxias V.
        • Voulgari P.V.
        • et al.
        Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12 week controlled study.
        Ann Rheum Dis. 2003; 62: 1204-1207
        • Ono M.
        • Takamura E.
        • Shinozaki K.
        • Tsumura T.
        • Hamano T.
        • Yagi Y.
        • et al.
        Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study.
        Am J Ophthalmol. 2004; 138: 6-17
        • Kruszka P.
        • O'Brian R.J.
        Diagnosis and management of Sjogren syndrome.
        Am Fam Physician. 2009; 79: 465-470
      2. Excellence NIfHaC. Raynaud's Phenomenon NICE Clinical Knowledge Summary. 2014 [cited; Available from: http://cks.nice.org.uk/raynauds-phenomenon – !scenario.

        • Guanabens N.
        • Pares A.
        • Ros I.
        • Caballeria L.
        • Pons F.
        • Vidal S.
        • et al.
        Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis.
        J Hepatol. 2005; 42: 573-577
        • Pares A.
        • Guanabens N.
        Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment.
        Clin Liver Dis. 2008; 12 (x): 407-424
        • Guanabens N.
        • Cerda D.
        • Monegal A.
        • Pons F.
        • Caballeria L.
        • Peris P.
        • et al.
        Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis.
        Gastroenterology. 2010; 138: 2348-2356
        • Guanabens N.
        • Monegal A.
        • Cerda D.
        • Muxi A.
        • Gifre L.
        • Peris P.
        • et al.
        Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
        Hepatology. 2013; 58: 2070-2078
        • Cryer B.
        • Bauer D.C.
        Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?.
        Mayo Clin Proc. 2002; 77: 1031-1043
        • Treeprasertsuk S.
        • Silveira M.G.
        • Petz J.L.
        • Lindor K.D.
        Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.
        Am J Ther. 2011; 18: 375-381
        • Pereira S.P.
        • O'Donohue J.
        • Moniz C.
        • Phillips M.G.
        • Abraha H.
        • Buxton-Thomas M.
        • et al.
        Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial.
        Aliment Pharmacol Ther. 2004; 19: 563-570
        • Newton J.
        • Francis R.
        • Prince M.
        • James O.
        • Bassendine M.
        • Rawlings D.
        • et al.
        Osteoporosis in primary biliary cirrhosis revisited.
        Gut. 2001; 49: 282-287
        • Kaplan M.M.
        • Elta G.H.
        • Furie B.
        • Sadowski J.A.
        • Russell R.M.
        Fat-soluble vitamin nutriture in primary biliary cirrhosis.
        Gastroenterology. 1988; 95: 787-792
        • Phillips J.R.
        • Angulo P.
        • Petterson T.
        • Lindor K.D.
        Fat-soluble vitamin levels in patients with primary biliary cirrhosis.
        Am J Gastroenterol. 2001; 96: 2745-2750
        • Maillette de Buy Wenniger L.
        • Beuers U.
        Bile salts and cholestasis.
        Dig Liver Dis. 2010; 42: 409-418
        • Jahn C.E.
        • Schaefer E.J.
        • Taam L.A.
        • Hoofnagle J.H.
        • Lindgren F.T.
        • Albers J.J.
        • et al.
        Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification.
        Gastroenterology. 1985; 89: 1266-1278
        • Kew M.C.
        • Varma R.R.
        • Dos Santos H.A.
        • Scheuer P.J.
        • Sherlock S.
        Portal hypertension in primary biliary cirrhosis.
        Gut. 1971; 12: 830-834
        • Gores G.J.
        • Wiesner R.H.
        • Dickson E.R.
        • Zinsmeister A.R.
        • Jorgensen R.A.
        • Langworthy A.
        Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival.
        Gastroenterology. 1989; 96: 1552-1559
        • Abraham S.C.
        • Kamath P.S.
        • Eghtesad B.
        • Demetris A.J.
        • Krasinskas A.M.
        Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy.
        Am J Surg Pathol. 2006; 30: 1454-1461
        • Ali A.H.
        • Sinakos E.
        • Silveira M.G.
        • Jorgensen R.A.
        • Angulo P.
        • Lindor K.D.
        Varices in early histological stage primary biliary cirrhosis.
        J Clin Gastroenterol. 2011; 45: e66-e71
        • Levy C.
        • Zein C.O.
        • Gomez J.
        • Soldevila-Pico C.
        • Firpi R.
        • Morelli G.
        • et al.
        Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis.
        Clin Gastroenterol Hepatol. 2007; 5: 803-808
        • Bressler B.
        • Pinto R.
        • El-Ashry D.
        • Heathcote E.J.
        Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?.
        Gut. 2005; 54: 407-410
        • de Franchis R.
        Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.
        J Hepatol. 2015; 63: 743-752
        • Jones D.E.
        • Metcalf J.V.
        • Collier J.D.
        • Bassendine M.F.
        • James O.F.
        Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes.
        Hepatology. 1997; 26: 1138-1142
      3. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma.
        J Hepatol. 2012; 56: 908-943
        • Adam R.
        • Karam V.
        • Delvart V.
        • O'Grady J.
        • Mirza D.
        • Klempnauer J.
        • et al.
        Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR).
        J Hepatol. 2012; 57: 675-688
        • Singal A.K.
        • Guturu P.
        • Hmoud B.
        • Kuo Y.F.
        • Salameh H.
        • Wiesner R.H.
        Evolving frequency and outcomes of liver transplantation based on etiology of liver disease.
        Transplantation. 2013; 95: 755-760
        • Carbone M.
        • Neuberger J.M.
        Autoimmune liver disease, autoimmunity and liver transplantation.
        J Hepatol. 2014; 60: 210-223
        • Martin P.
        • DiMartini A.
        • Feng S.
        • Brown Jr., R.
        • Fallon M.
        Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.
        Hepatology. 2014; 59: 1144-1165
        • European Association for the Study of the Liver
        Electronic address eee. EASL Clinical Practice Guidelines: Liver transplantation.
        J Hepatol. 2016; 64: 433-485
        • Pells G.
        • Mells G.F.
        • Carbone M.
        • Newton J.L.
        • Bathgate A.J.
        • Burroughs A.K.
        • et al.
        The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.
        J Hepatol. 2013; 59: 67-73
        • Lucey M.R.
        • Terrault N.
        • Ojo L.
        • Hay J.E.
        • Neuberger J.
        • Blumberg E.
        • et al.
        Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.
        Liver Transpl. 2013; 19: 3-26
        • Silveira M.G.
        • Talwalkar J.A.
        • Lindor K.D.
        • Wiesner R.H.
        Recurrent primary biliary cirrhosis after liver transplantation.
        Am J Transplant. 2010; 10: 720-726
        • Bosch A.
        • Dumortier J.
        • Maucort-Boulch D.
        • Scoazec J.Y.
        • Wendum D.
        • Conti F.
        • et al.
        Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
        J Hepatol. 2015; 63: 1449-1458
        • Pearce R.M.
        • Jones D.E.
        • Newton J.L.
        Development of an evidence-based patient information medium: empowering newly diagnosed patients with primary biliary cirrhosis.
        J Vis Commun Med. 2011; 34: 4-13
        • Blackburn P.
        • Freeston M.
        • Baker C.R.
        • Jones D.E.
        • Newton J.L.
        The role of psychological factors in the fatigue of primary biliary cirrhosis.
        Liver Int. 2007; 27: 654-661